We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cara

News List

US clears Cara, Vifor's Korsuva to treat itching in CKD patients firstwordpharma
August 24, 2021
Cara Therapeutics and Vifor Pharma said Monday that the FDA has approved Korsuva (difelikefalin) to treat moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis.
Enteris BioPharma Receives $10M Milestone from Cara Therapeutics contractpharma
June 15, 2021
The contract development and manufacturing organization (CDMO) Enteris BioPharma received a $10 million milestone payment from Cara Therapeutics related to the license agreement for the Peptelligence oral formulation technology utilized in ...
Cara Therapeutics Announces Positive Topline Data from Oral KORSUVA Trial americanpharmaceuticalreview
December 30, 2019
Cara Therapeutics announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with ...
Enteris, Cara Therapeutics Enter Peptelligence Pact contractpharma
August 27, 2019
Cara has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA